Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Will support manufacture of BCX4430 for trials
March 31, 2015
By: Kristin Brooks
Managing Editor, Contract Pharma
BioCryst Pharmaceuticals, Inc. has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This contract includes a base contract of $12.1 million to support BCX4430 drug manufacturing, as well as $22.9 million in additional development options that can be exercised by the Government. Filoviruses represent serious threats to national security and the U.S. Government has made this a top priority for medical countermeasure development. The base contract focuses on drug manufacturing, including process improvement, scale up and manufacture of BCX4430 for clinical studies and non-clinical toxicology studies supporting the filing of a New Drug Application (NDA) with the FDA for both intravenous and intramuscular formulations. “BCX4430 currently represents the only single drug that has demonstrated a survival benefit in non-human primates infected with Marburg or Ebola viruses,” said Jon P. Stonehouse, president and chief executive officer of BioCryst. “This new BARDA contract provides continuity in the ongoing development of our broad spectrum antiviral, ‘4430, and moves this program closer to the finish line.” A Phase I trial of BCX4430 in healthy volunteers was initiated in December 2014 to evaluate the safety and tolerability of intramuscular administration. Results from a Phase I trial are expected in 3Q15.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !